「小普日报」2023年11月1日热点速递
关键词 逆转录因子 内分泌 干扰素调节因子 饱和突变 PD-1检查点 曲妥珠单抗 多塔利单抗 恩沃利单抗
#今日行业热点#
①Science：Genome editing with retroelements 观点：利用逆转录因子进行基因组编辑 DOI: 10.1126/science.adi3183
Genome editing with retroelements | Science
②Science：Unbiased transcription factor CRISPR screen identifies ZNF800 as master repressor of enteroendocrine differentiation 基于CRISPR的功能筛选确定ZNF800是调控内分泌转录因子网络的关键因子 DOI: 10.1126/science.adi2246
Unbiased transcription factor CRISPR screen identifies ZNF800 as master repressor of enteroendocrine differentiation | Science
③Science Advances：IRF1 regulates self-renewal and stress responsiveness to support hematopoietic stem cell maintenance 干扰素调节因子1 (IRF1)通过调节自我更新和应激反应来支持造血干细胞(HSCs)的维持 DOI: 10.1126/sciadv.adg5391
IRF1 regulates self-renewal and stress responsiveness to support hematopoietic stem cell maintenance | Science Advances
④Science Advances：Saturation mutagenesis of α-synuclein reveals monomer fold that modulates aggregation α-突触核蛋白(aSyn)饱和突变揭示了调节aSyn聚集的调节因子 DOI: 10.1126/sciadv.adh3457
Saturation mutagenesis of α-synuclein reveals monomer fold that modulates aggregation | Science Advances
⑤Science Advances：Stromal BMP signaling regulates mucin production in the large intestine via interleukin-1/17 基质骨形态发生蛋白(BMP)信号通过IL-1和IL-17调节大肠黏蛋白的产生 DOI: 10.1126/sciadv.adi1827
Stromal BMP signaling regulates mucin production in the large intestine via interleukin-1/17 | Science Advances
⑥Science Translational Medicine：DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity DGKα/ζ抑制剂联合PD-1检查点疗法促进T细胞介导的抗肿瘤免疫 DOI: 10.1126/scitranslmed.adh1892
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity | Science Translational Medicine
⑦曲妥珠单抗生物类似药上市申请已获得批准；同时申请适应症外推，拟定适应症为：HER2阳性早期乳腺癌、HER2阳性转移性乳腺癌、HER2阳性转移性胃癌 ⑧PD-1抑制剂多塔利单抗(Dostarlimab)用于原发性晚期或复发性子宫内膜癌的Ⅲ期临床RUBY达到总生存期（OS）的主要终点 ⑨高选择性内皮素A（ETA）受体抑制剂Atrasentan用于IgA肾病的III期ALIGN研究达到主要终点 ⑩PD-L1抗体恩沃利单抗获FDA批准开展Ⅲ期临床，评估恩沃利单抗联合仑伐替尼对比铂类用于错配修复完整（pMMR）晚期或复发性子宫内膜癌患者的有效性与安全性 科学探索的世界充满挑战，AtaGenix致敬每一位拓荒者，更致力于成为
